Valbenazine - Neurocrine Biosciences

Drug Profile

Valbenazine - Neurocrine Biosciences

Alternative Names: INGREZZA; MT 5199; NBI-98854; Valbenazine-tosylate; VMAT2-inhibtor-Neurocrine-Biosciences

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
  • Class 3-ring heterocyclic compounds; Amino acids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Huntington's disease; Schizophrenia

Most Recent Events

  • 08 Feb 2018 Neurocrine Biosciences initiates a phase IIb trial for Gilles de la Tourette's syndrome (In adolescents, In children) in USA (NCT03444038)
  • 04 Dec 2017 Adverse events data from a pooled analysis of phase II and III KINECT, KINECT 2 and KINECT 3 trials in Drug-induced dyskinesia released by Neurocrine Biosciences
  • 04 Dec 2017 Safety and efficacy data from the phase III KINECT 4 trial in Drug-induced dyskinesia released by Neurocrine Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top